Reviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the target of unusually large options trading activity on Tuesday. Stock investors acquired 13,196 call options on the stock. This represents an increase of approximately 374% compared to the average daily volume of 2,782 call options.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently bought a new stake in Reviva Pharmaceuticals stock. Drive Wealth Management LLC bought a new position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $36,000. Drive Wealth Management LLC owned about 0.06% of Reviva Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Down 3.0 %

Reviva Pharmaceuticals stock opened at $1.94 on Thursday. The stock has a market cap of $64.88 million, a PE ratio of -1.75 and a beta of -0.12. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.83. The business’s 50-day moving average price is $1.68 and its two-hundred day moving average price is $1.33.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on RVPH shares. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. HC Wainwright cut their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday. Roth Mkm initiated coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday. Finally, Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, January 10th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.40.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.